MA51519A - Animaux c5 et c3 humanisés - Google Patents

Animaux c5 et c3 humanisés

Info

Publication number
MA51519A
MA51519A MA051519A MA51519A MA51519A MA 51519 A MA51519 A MA 51519A MA 051519 A MA051519 A MA 051519A MA 51519 A MA51519 A MA 51519A MA 51519 A MA51519 A MA 51519A
Authority
MA
Morocco
Prior art keywords
humanized
animals
Prior art date
Application number
MA051519A
Other languages
English (en)
Inventor
Jingtai Cao
Ying Hu
Adrianna Latuszek
Lynn Macdonald
John Mcwhirter
Karolina Meagher
Alexander Mujica
Andrew Murphy
Stanley Wiegand
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA51519A publication Critical patent/MA51519A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
MA051519A 2014-05-05 2015-05-04 Animaux c5 et c3 humanisés MA51519A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461988581P 2014-05-05 2014-05-05
US201462067836P 2014-10-23 2014-10-23

Publications (1)

Publication Number Publication Date
MA51519A true MA51519A (fr) 2020-11-11

Family

ID=53177902

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051519A MA51519A (fr) 2014-05-05 2015-05-04 Animaux c5 et c3 humanisés

Country Status (15)

Country Link
US (5) US9795121B2 (fr)
EP (3) EP3142483B1 (fr)
JP (1) JP6598798B2 (fr)
KR (1) KR102461511B1 (fr)
CN (1) CN106659146B (fr)
AU (1) AU2015256299C1 (fr)
BR (1) BR112016025751A2 (fr)
CA (2) CA3225091A1 (fr)
ES (2) ES2779070T3 (fr)
IL (1) IL248481B (fr)
MA (1) MA51519A (fr)
MX (2) MX386644B (fr)
RU (2) RU2020103811A (fr)
SG (2) SG10202003996YA (fr)
WO (1) WO2015171523A1 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
BR112016025751A2 (pt) 2014-05-05 2018-01-16 Regeneron Pharma roedor, e, métodos para fabricar um roedor e um camundongo humanizados e para identificar um composto capaz de modular a ativação de complemento
NO2785538T3 (fr) 2014-05-07 2018-08-04
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017132155A1 (fr) * 2016-01-25 2017-08-03 President And Fellows Of Harvard College Procédés et compositions de détection et de traitement de la schizophrénie
AU2017283470B2 (en) 2016-06-14 2024-03-21 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies and uses thereof
WO2018039499A1 (fr) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Modification de protéines de cellules hôtes
SG11201907606XA (en) * 2017-02-27 2019-09-27 Regeneron Pharma Humanized model of kidney and liver disorders
KR102659791B1 (ko) 2017-07-06 2024-04-23 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
ES2961713T3 (es) 2017-09-29 2024-03-13 Regeneron Pharma Roedores que expresan el complejo C1Q humanizado
SG11202000771UA (en) 2017-09-29 2020-04-29 Regeneron Pharma Non-human animals comprising a humanized ttr locus and methods of use
CN107736281A (zh) * 2017-09-29 2018-02-27 中国水产科学研究院珠江水产研究所 一种利用益生菌发酵酱油渣防治池塘养殖鳜鱼寄生虫的方法
WO2019118556A1 (fr) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Associations d'anticorps anti-c5 et utilisations associées
CN111479618B (zh) 2017-12-22 2022-08-02 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
EA202091689A1 (ru) 2018-01-31 2020-10-22 Ридженерон Фармасьютикалз, Инк. Система и способ определения характеристик примесей, представляющих собой варианты, отличающиеся по размеру и заряду, в продукте, представляющем собой лекарственное средство
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
MX2020008988A (es) 2018-02-28 2020-09-28 Regeneron Pharma Sistemas y metodos para la identificacion de contaminantes virales.
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
MY202358A (en) 2018-03-19 2024-04-24 Regeneron Pharma Microchip capillary electrophoresis assays and reagents
SG11202008897SA (en) 2018-04-03 2020-10-29 Ngm Biopharmaceuticals Inc C3-binding agents and methods of use thereof
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
JP7634994B2 (ja) 2018-07-16 2025-02-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｉｔｒａの非ヒト動物モデルおよびその使用
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
BR112020026348A2 (pt) 2018-08-30 2021-03-30 Regeneron Pharmaceuticals, Inc. Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica
SG11202101853PA (en) * 2018-09-06 2021-03-30 Univ Pennsylvania Humanized anti-c5 antibodies and uses thereof
AU2020208396A1 (en) 2019-01-16 2021-05-20 Regeneron Pharmaceuticals, Inc. Methods for identifying free thiols in proteins
ES2966625T3 (es) 2019-04-04 2024-04-23 Regeneron Pharma Roedores que comprenden un locus del factor de coagulación 12 humanizado
BR112021021176A2 (pt) * 2019-04-24 2021-12-28 Kira Pharmaceuticals Us Llc Proteína de fusão, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema de complemento de um indivíduo, célula, e, animal não humano geneticamente modificado
CN113785203A (zh) 2019-05-13 2021-12-10 里珍纳龙药品有限公司 改进的竞争性配体结合测定
AU2020286382B2 (en) 2019-06-04 2026-03-26 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use
JP7698587B2 (ja) 2019-06-07 2025-06-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化アルブミン遺伝子座を含む非ヒト動物
PH12022550630A1 (en) 2019-09-24 2023-03-27 Regeneron Pharma Systems and methods for chromatography use and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN114760986A (zh) 2019-11-25 2022-07-15 里珍纳龙药品有限公司 使用非水性乳液的持续释放调配物
EP4354145B1 (fr) 2020-01-21 2025-09-17 Regeneron Pharmaceuticals, Inc. Procédés de déglycosylation pour l'électrophorèse de protéines glycosylées
BR112023003273A2 (pt) 2020-08-31 2023-05-02 Regeneron Pharma Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
US12082566B2 (en) 2020-10-01 2024-09-10 Regeneron Pharmaceuticals, Inc. Rodent animals expressing human CR1
MX2023006077A (es) 2020-11-25 2023-06-06 Regeneron Pharma Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
US12031151B2 (en) 2021-01-20 2024-07-09 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
WO2022187323A1 (fr) 2021-03-03 2022-09-09 Regeneron Pharmaceuticals, Inc. Systèmes et procédés de quantification et de modification de la viscosité de protéines
CA3211302A1 (fr) 2021-03-26 2022-09-29 Ross Kenyon Procedes et systemes pour developper des protocoles de melange
BR112023024984A2 (pt) 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
EP4405390A1 (fr) 2021-09-20 2024-07-31 Regeneron Pharmaceuticals, Inc. Procédés de contrôle de l'hétérogénéité d'anticorps
WO2023059803A1 (fr) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Étalonnage et correction de ph-mètre
EP4413364A2 (fr) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Systèmes et méthodes de modélisation et de régulation du ph
MX2024005090A (es) 2021-10-26 2024-07-19 Regeneron Pharma Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
CN118251491A (zh) 2021-10-28 2024-06-25 瑞泽恩制药公司 用于敲除C5的CRISPR/Cas相关方法及组合物
JP2025508233A (ja) 2022-03-18 2025-03-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ポリペプチド変異体を分析するための方法およびシステム
CN120418653A (zh) 2022-12-16 2025-08-01 里珍纳龙药品有限公司 评估色谱柱完整性的方法和系统
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024158961A1 (fr) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Caractérisation basée sur la spectrométrie de masse d'anticorps co-exprimés in vivo
TW202446462A (zh) 2023-02-22 2024-12-01 美商再生元醫藥公司 系統適用性參數及管柱老化
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (fr) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Procédés et systèmes pour développer des protocoles de chromatographie
TW202532098A (zh) 2023-09-29 2025-08-16 美商再生元醫藥公司 使用控制成核之冷凍乾燥
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
AR134213A1 (es) 2023-11-02 2025-12-10 Regeneron Pharma Métodos para reducir la actividad de la lipasa mediante estrés
WO2025122669A1 (fr) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Animaux non humains ayant un gène du facteur b du complément humanisé
WO2025166281A1 (fr) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Plateforme d'analyse par spectrométrie de masse à détection de charge d'aavs
WO2025175164A1 (fr) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Procédés de production de substances médicamenteuses formulées concentrées comprenant des protéines, et substance médicamenteuse formulée concentrée fabriquée par les procédés
WO2025194043A1 (fr) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate et polyoxyéthylène sorbitane utilisés en tant qu'excipients pour formulations de protéines stables
WO2025259840A1 (fr) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Procédés et systèmes de chromatographie mise à l'échelle
WO2026025028A1 (fr) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Procédés de fabrication de formulations protéiques à concentration ultra-élevée par lyophilisation
WO2026060350A1 (fr) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Procédés d'amélioration de la photostabilité et de contrôle de la formation d'espèces hmw dans des formulations biologiques, et formulations biologiques produites par les procédés

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
WO1984003506A1 (fr) 1983-03-08 1984-09-13 Commw Serum Lab Commission Sequences d'acides amines antigeniquement actives
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3590766T (fr) 1985-03-30 1987-04-23
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0558671T3 (da) 1990-11-21 1999-09-13 Iterex Pharma Lp Syntese af ækvimolære multiple oligomerblandinger, især af oligopeptidblandinger
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6166288A (en) * 1995-09-27 2000-12-26 Nextran Inc. Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor
GB9521943D0 (en) 1995-10-26 1996-01-03 Univ Hertfordshire Coded particles for process sequence tracking in combinatorial compound library preparation
CA2323757C (fr) 1998-04-02 2011-08-02 Genentech, Inc. Variants d'anticorps et fragments de ceux-ci
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6280946B2 (en) 1998-08-07 2001-08-28 Boston Probes, Inc. PNA probes, probe sets, methods and kits pertaining to the universal detection of bacteria and eucarya
JP2002533726A (ja) 1998-12-28 2002-10-08 サネシス ファーマシューティカルス インコーポレイテッド 結合のための小有機分子リガンドの同定
WO2005060739A1 (fr) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Mammifere transgenique non humain comprenant un polynucleotide codant pour un recepteur c5ar humain ou humanise
PT1713503E (pt) 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
EP1976626A2 (fr) 2006-01-11 2008-10-08 Novo Nordisk A/S Billes codées sphériques améliorées
WO2009103113A1 (fr) * 2008-02-20 2009-08-27 G2 Inflammation Pty Ltd Anticorps anti-c5ar humanisés
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
DK3056082T3 (en) 2009-10-06 2018-12-17 Regeneron Pharma RE-MODIFIED MICE AND INPUT
EP2675271B1 (fr) 2011-02-15 2018-06-13 Regeneron Pharmaceuticals, Inc. SOURIS HUMANISÉES QUANT AU M-CSF (Macrophage colony-stimulating factor)
PT2770821T (pt) 2011-10-28 2017-12-18 Regeneron Pharma Ratinhos de complexo principal de histocompatibilidade principal modificados geneticamente
PT2818478T (pt) 2011-10-28 2017-05-12 Regeneron Pharma Il-6 e recetor de il-6 humanizados
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
AU2013312359B8 (en) 2012-09-07 2019-08-15 Institute For Research In Biomedicine (Irb) Genetically modified non-human animals and methods of use thereof
SG11201502685XA (en) 2012-11-05 2015-05-28 Regeneron Pharma Genetically modified non-human animals and methods of use thereof
RS57963B1 (sr) 2013-02-22 2019-01-31 Regeneron Pharma Miševi koji eksprimiraju humanizovani glavni kompleks histokompatibilnosti
WO2015057758A1 (fr) 2013-10-15 2015-04-23 Regeneron Pharmaceuticals, Inc. Animaux humanisés il-15
KR102173297B1 (ko) 2013-11-19 2020-11-03 리제너론 파마슈티칼스 인코포레이티드 인간화된 증식-유도 리간드 유전자를 가지고 있는 비-인간 동물
BR112016025751A2 (pt) * 2014-05-05 2018-01-16 Regeneron Pharma roedor, e, métodos para fabricar um roedor e um camundongo humanizados e para identificar um composto capaz de modular a ativação de complemento

Also Published As

Publication number Publication date
KR20170002472A (ko) 2017-01-06
EP3142483A1 (fr) 2017-03-22
RU2713327C2 (ru) 2020-02-04
MX2016014504A (es) 2017-05-23
US11178860B2 (en) 2021-11-23
US20170332611A1 (en) 2017-11-23
EP3636073B1 (fr) 2023-11-15
MX386644B (es) 2025-03-19
US10492477B2 (en) 2019-12-03
KR102461511B1 (ko) 2022-11-01
ES2968749T3 (es) 2024-05-13
CA2946412A1 (fr) 2015-11-12
BR112016025751A2 (pt) 2018-01-16
CN106659146A (zh) 2017-05-10
EP3636073A1 (fr) 2020-04-15
IL248481A0 (en) 2016-12-29
NZ726602A (en) 2024-05-31
US20180332833A1 (en) 2018-11-22
US20200037587A1 (en) 2020-02-06
SG11201608696RA (en) 2016-11-29
US20220132818A1 (en) 2022-05-05
EP3636073C0 (fr) 2023-11-15
RU2016146390A3 (fr) 2018-11-22
US10524458B2 (en) 2020-01-07
RU2020103811A (ru) 2020-02-18
IL248481B (en) 2021-04-29
ES2779070T3 (es) 2020-08-13
CN106659146B (zh) 2020-06-23
RU2016146390A (ru) 2018-06-06
AU2015256299A1 (en) 2016-12-08
NZ763860A (en) 2024-05-31
JP2017514496A (ja) 2017-06-08
EP4317445A2 (fr) 2024-02-07
EP4317445A3 (fr) 2024-05-15
AU2015256299B2 (en) 2021-09-23
JP6598798B2 (ja) 2019-10-30
AU2015256299C1 (en) 2022-01-06
US20150313194A1 (en) 2015-11-05
CA3225091A1 (fr) 2015-11-12
EP3142483B1 (fr) 2020-01-22
WO2015171523A1 (fr) 2015-11-12
CA2946412C (fr) 2024-02-27
SG10202003996YA (en) 2020-06-29
US9795121B2 (en) 2017-10-24

Similar Documents

Publication Publication Date Title
NL301117I1 (nl) trastuzumab deruxtecan
MA51519A (fr) Animaux c5 et c3 humanisés
IL284727B (en) Noise suppression methods and apparatus
IL258437B (en) Growing systems and methods
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
IL251963A0 (en) Anti-pd-1 antibodies
LT3097119T (lt) Žmogaus antikūnai prieš pd-1
DK3212255T3 (da) Selvorienterende sprøjte og sprøjtegrænseflade
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
PL3653221T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
PT3215532T (pt) Anticorpos anti-tim3 e métodos de utilização
DK3560954T3 (da) Modificeret j-kæde
IL248781B (en) Pesticidal compositions and related methods
HRP20251683T1 (hr) Humanizirana anti-acth antitijela i njihova uporaba
DK3151875T3 (da) Humane lever-scaffolds
IL291164A (en) Anti-nme antibody
PL3280440T3 (pl) Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
PL3092003T3 (pl) Nowe przeciwciało przeciw netrynie-1
DK3136845T3 (da) Fjerkræstrøelse
HUE054148T2 (hu) Anti-ORAI1 antitest
LT3126391T (lt) Hpa-1a antikūnai
DK3235799T3 (da) Oximforbindelse og herbicid
ES1101930Y (es) Pulsera portagomas
DK2965607T3 (da) Såmaskine